Novo Nordisk’s Awiqli Gets FDA Approval for Type II Diabetes
Novo Nordisk NVO announced that the FDA has approved Awiqli injection as the first and only once-weekly, long-acting basal…
Novo Nordisk’s Awiqli Gets FDA Approval for Type II Diabetes
Novo Nordisk NVO announced that the FDA has approved Awiqli injection as the first and only once-weekly, long-acting basal…
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk NVO and its partner, The United Laboratories International Holdings Limited (“TUL”), jointly announced top-line data from…